US 12,419,920 B2
Bifidobacterium longum NCIMB 41676
Eileen Frances Murphy, Cork (IE); Paul Enck, Berlin (DE); Christoph Braun, Tuebingen (DE); and Huiying Wang, Shanghai (CN)
Assigned to PrecisionBiotics Group Limited, Cork (IE)
Filed by PrecisionBiotics Group Limited, Cork (IE)
Filed on Aug. 24, 2023, as Appl. No. 18/455,329.
Application 18/455,329 is a continuation of application No. 16/767,874, granted, now 11,771,723, previously published as PCT/EP2019/052138, filed on Jan. 29, 2019.
Claims priority of application No. 18153993 (EP), filed on Jan. 29, 2018.
Prior Publication US 2023/0414681 A1, Dec. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/745 (2015.01); A23L 33/135 (2016.01); A23L 33/21 (2016.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 39/39 (2006.01)
CPC A61K 35/745 (2013.01) [A23L 33/135 (2016.08); A23L 33/21 (2016.08); A61K 39/39 (2013.01); A61K 9/0053 (2013.01); A61K 9/14 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01)] 20 Claims
 
1. A method of treating a subject, the method comprising administering to the subject a formulation comprising Bifidobacterium longum strain having the accession number NCIMB 41676 and a carrier, wherein the formulation reduces mental fatigue in the subject as measured by an increase in theta band resting state brain oscillations in the frontal and cingulate cortex or a decrease in beta-3 resting state brain oscillations in the hippocampus, fusiform, and temporal cortex.